Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.60 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.47 |
| ▸ | CDK2 | P24941 | 5/20 | 0.47 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 7/20 | 0.45 |
| ▸ | GSK3B | P49841 | 6/20 | 0.45 |
| ▸ | WNT1 | P04628 | 4/20 | 0.45 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.44 |
| ▸ | OGA | O60502 | 4/20 | 0.43 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25220645 | 0.85 | SMN1; SMN2 (0.51) | MKNK1CCNE1CDK2CCNE2SMN1; SMN2 | |
| SCHEMBL25859144 | 0.77 | MKNK1 (0.64) | MKNK1CCNE1CDK2CCNE2SMN1; SMN2 | |
| SCHEMBL10226337 | 0.76 | MKNK1 (0.62) | MKNK1CCNE1CDK2CCNE2SMN1; SMN2 | |
| SCHEMBL20883052 | 0.74 | SMN1; SMN2 (0.66) | CCNE1CDK2SMN1; SMN2CDK5CDK5R1 | |
| SCHEMBL20883077 | 0.74 | SMN1; SMN2 (0.66) | CCNE1CDK2SMN1; SMN2CDK5CDK5R1 | |
| SCHEMBL24246502 | 0.74 | SMN1; SMN2 (0.61) | CCNE1CDK2SMN1; SMN2CDK5CDK5R1 | |
| SCHEMBL25609256 | 0.72 | MKNK1 (0.81) | MKNK1CCNE1CDK2CCNE2DYRK1A | |
| SCHEMBL31272043 | 0.71 | MKNK1 (0.66) | MKNK1CCNE1CDK2CCNE2SMN1; SMN2 | |
| SCHEMBL22522759 | 0.70 | SMN1; SMN2 (0.53) | CCNE1CDK2SMN1; SMN2CDK5CDK5R1 | |
| SCHEMBL25606129 | 0.70 | MKNK1 (0.77) | MKNK1CCNE1CDK2CCNE2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066318-A1 | HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS | PROTHENA BIOSCIENCES INC | 2025-02-27 | — | — | US | disclosed |
| CN-118843626-A | Heterocyclic compounds as DYRK1A inhibitors | 普罗塞纳生物科学有限公司 | 2024-10-25 | — | — | CN | disclosed |
| EP-4444421-A2 | HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS | Prothena Biosciences Limited (IE) | 2024-10-16 | — | — | EP | disclosed |
| WO-2023107714-A2 | METHODS FOR TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023107714-A2 | METHODS FOR TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2023-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066318-A1 | HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS | DYRK1A, DYRK2, DYRK1B | MKNK1 105/4885CCNE1 1546/4885CDK2 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.